|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007634,
umls-concept:C0010868,
umls-concept:C0023434,
umls-concept:C0205225,
umls-concept:C0243071,
umls-concept:C0439849,
umls-concept:C0441655,
umls-concept:C0445223,
umls-concept:C1442989,
umls-concept:C1552599,
umls-concept:C1704787,
umls-concept:C1871955,
umls-concept:C2000248
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2007-7-19
|
|
pubmed:abstractText |
SDX-101 is the non-cyclooxygenase 2-inhibiting R-enantiomer of the non-steroid anti-inflammatory drug etodolac, and has anti-tumour activity in chronic lymphocytic leukaemia (CLL). SDX-308 and SDX-309 are more potent, structurally related indole-pyran analogues of SDX-101. The current study was performed to investigate and quantify the cytotoxic potentiating effects resulting from a combination of either SDX-101, SDX-308 or SDX-309 with standard cytotoxic agents used in the CLL treatment today.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
545-53
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:17186240-Aged,
pubmed-meshheading:17186240-Aged, 80 and over,
pubmed-meshheading:17186240-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17186240-Cell Line, Tumor,
pubmed-meshheading:17186240-Chlorambucil,
pubmed-meshheading:17186240-Doxorubicin,
pubmed-meshheading:17186240-Drug Synergism,
pubmed-meshheading:17186240-Etodolac,
pubmed-meshheading:17186240-Female,
pubmed-meshheading:17186240-Heterocyclic Compounds, 3-Ring,
pubmed-meshheading:17186240-Humans,
pubmed-meshheading:17186240-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:17186240-Lymphoma,
pubmed-meshheading:17186240-Male,
pubmed-meshheading:17186240-Middle Aged,
pubmed-meshheading:17186240-Vincristine
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells.
|
|
pubmed:affiliation |
Division of Clinical Pharmacology, Uppsala University, Uppsala, Sweden. elin.lindhagen@medsci.uu.se
|
|
pubmed:publicationType |
Journal Article
|
